Satyajit Kosuri

Satyajit Kosuri is an Assistant Professor in the Department of Medicine-Hematology and Oncology at the University of Chicago. His research focuses on hematologic malignancies, particularly acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and the application of stem cell transplantation and targeted therapies. He has contributed to the understanding of genetic factors (e.g., DDX41, TP53, FLT3 mutations) in cancer risk and treatment response. His work emphasizes translational research, including optimizing CAR-T cell therapy, geriatric assessment for older patients, and novel therapeutic combinations.

Key research interests include molecular minimal residual disease testing, FLT3 inhibitor maintenance in AML, and the outcomes of allogeneic hematopoietic cell transplantation in genetically defined patient populations. He has published extensively in journals like Blood Advances and Haematologica, with a focus on clinical trials evaluating new therapies (e.g., selinexor, venetoclax) and transplant-related toxicities.

His recent studies address challenges in managing neurotoxicity from CAR-T therapy, late toxicities after stem cell transplantation, and the role of germline mutations in cancer predisposition. Collaborations include co-authors like Derman, Bishop, and Stock, focusing on multidisciplinary approaches to hematologic malignancies.